Top

Published in:

01-01-2020 | Amyotrophic Lateral Sclerosis | Original Article

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients

Authors: Jin-Mo Park, Sun-Young Kim, Donghwi Park, Jin-Sung Park

Published in: Neurological Sciences | Issue 1/2020

Abstract

Oxidative stress caused by free radicals has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Edaravone (also known as MCI-186), a free radical scavenger, was approved as an ALS treatment in 2015 in Japan. However, the therapeutic effects of edaravone on patients with ALS outside of Japan are not yet reported. This study aims to investigate effects of edaravone on ALS patients in the Korean population. The study included 22 patients with ALS who were treated with edaravone. Of the 16 patients who finished six cycles of treatment, a mean decline of ALSFRS-R after the treatments was 5.75 ± 6.07 points and the average change of FVC was − 8.7 ± 17.0%. Patients experienced only minor adverse events. This study reports on the open-label study of edaravone on patients in Korea for ALS patients, which showed a modest effect of edaravone in this population of ALS patients.

Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377:162–172CrossRef

Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42:644–654CrossRef

Ikawa M, Okazawa H, Tsujikawa T et al (2015) Increased oxidative stress is related to disease severity in the ALS motor cortex: a PET study. Neurology 84:2033–2039CrossRef

Fujisawa A, Yamamoto Y (2016) Edaravone a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-Edaravone. Redox Rep 21:98–103CrossRef

Writing Group; Edaravone (MCI-186) ALS 19 Study Group (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:505–512CrossRef

Brooks BR, Miller RG, Swash M, Munsat TL (2000) World Federation of Neurology Research Group on motor neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299CrossRef

Amin Lari A, Ghavanini AA, Bokaee HR (2019) A review of electrophysiological studies of lower motor neuron involvement in amyotrophic lateral sclerosis. Neurol Sci 40:1125–1136CrossRef

Bacci ED, Staniewska D, Coyne KS, Boyer S, White LA, Zach N, Pooled Resource Open-Access ALS Clinical Trials Consortium et al (2016) Item response theory analysis of the amyotrophic lateral sclerosis functional rating scale-revised in the pooled resource open-access ALS clinical trials database. Amyotroph Lateral Scler Frontotemporal Degener 17:157–167CrossRef

Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowwicz ME (2010) Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler 11:178–180CrossRef

10.

Park JS, Do YW, Park JM, Seok HY, Park D (2019) Under-recognized primary spontaneous pneumothorax in ALS: a multicenter retrospective study. Neurol Sci. https://doi.org/10.1007/s10072-019-03989-y CrossRef

11.

Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y (2018) Long-term effects of Edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci 11:11–14CrossRef

12.

Luo L, Song Z, Li X et al (2018) Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis – a systemic review and meta-analysis. Neurol Sci 40:235–241CrossRef

13.

Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J (2017) Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of Edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 18:49–54CrossRef

14.

Writing group on behalf of the edaravone (MCI-186) ALS 18 study group (2017) Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener 18:40–48CrossRef

15.

Takei K, Tsuda K, Takahashi F, Hirai M, Palumbo J (2017) An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener 18:88–97CrossRef

16.

Watanabe H, Atsuta N, Hirakawa A, Nakamura R, Nakatochi M, Ishigaki S, Iida A, Ikegawa S, Kubo M, Yokoi D, Watanabe H, Ito M, Katsuno M, Izumi Y, Morita M, Kanai K, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Kawata A, Aoki M, Tsuji S, Nakashima K, Kaji R, Sobue G (2016) A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J Neurol Neurosurg Psychiatry 87:851–858CrossRef

Title: Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
Authors: Jin-Mo Park
Sun-Young Kim
Donghwi Park
Jin-Sung Park
Publication date: 01-01-2020
Publisher: Springer International Publishing
Keyword: Amyotrophic Lateral Sclerosis
Published in: Neurological Sciences / Issue 1/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-019-04055-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Highlights of the issue 1, 2020

Hashimoto’s thyroiditis associated with acute painful unilateral ophthalmoplegia

False-positive anti-NMDA receptor antibodies in severe case of Lyme neuroborreliosis

Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review

Evidence for hyperprolactinemia in migraineurs: a systematic review and meta-analysis

Population-based study of environmental/occupational lead exposure and amyotrophic lateral sclerosis: a systematic review and meta-analysis